Nexcella Inc.
Nexcella Inc.
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis | Nutritional and Metabolic Diseases, amyloidosis, metabolic disease, proteostasis deficiencies | Not yet recruiting | Phase 3 | 2026-07-16 | NCT07709715 | |
| Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Active, not recruiting | Phase 1 / Phase 2 | 2026-07-14 | NCT06097832 | |
| NXC-201 (formerly HBI0101) Multiple Myeloma | Dose Escalation and Safety | Active, not recruiting | Phase 1 | 2025-03-14 | NCT04720313 |